Zentalis Pharmaceuticals ... (ZNTL)
Zentalis Pharmaceuticals Statistics
Share Statistics
Zentalis Pharmaceuticals has 71.81M shares outstanding. The number of shares has increased by 1.12% in one year.
| Shares Outstanding | 71.81M |
| Shares Change (YoY) | 1.12% |
| Shares Change (QoQ) | 0.77% |
| Owned by Institutions (%) | 90.59% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 98 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 5.27M, so 7.33% of the outstanding shares have been sold short.
| Short Interest | 5.27M |
| Short % of Shares Out | 7.33% |
| Short % of Float | 14.65% |
| Short Ratio (days to cover) | 6.12 |
Valuation Ratios
The PE ratio is -1.3 and the forward PE ratio is -0.57. Zentalis Pharmaceuticals's PEG ratio is 0.03.
| PE Ratio | -1.3 |
| Forward PE | -0.57 |
| PS Ratio | 3.19 |
| Forward PS | 0.6 |
| PB Ratio | 0.64 |
| P/FCF Ratio | -1.26 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Zentalis Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.32, with a Debt / Equity ratio of 0.12.
| Current Ratio | 7.32 |
| Quick Ratio | 7.32 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.21 |
| Debt / FCF | -0.23 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $406,174.7 |
| Profits Per Employee | $-999,030.12 |
| Employee Count | 166 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 177K |
| Effective Tax Rate | -0.11% |
Stock Price Statistics
The stock price has increased by -86.86% in the last 52 weeks. The beta is 1.8, so Zentalis Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.8 |
| 52-Week Price Change | -86.86% |
| 50-Day Moving Average | 1.66 |
| 200-Day Moving Average | 2.81 |
| Relative Strength Index (RSI) | 49.15 |
| Average Volume (20 Days) | 1,077,401 |
Income Statement
In the last 12 months, Zentalis Pharmaceuticals had revenue of 67.42M and earned -165.84M in profits. Earnings per share was -2.33.
| Revenue | 67.42M |
| Gross Profit | 67.42M |
| Operating Income | -191.19M |
| Net Income | -165.84M |
| EBITDA | -186.17M |
| EBIT | -187.46M |
| Earnings Per Share (EPS) | -2.33 |
Balance Sheet
The company has 33.9M in cash and 39.58M in debt, giving a net cash position of -5.68M.
| Cash & Cash Equivalents | 33.9M |
| Total Debt | 39.58M |
| Net Cash | -5.68M |
| Retained Earnings | -1.05B |
| Total Assets | 430.34M |
| Working Capital | 333.34M |
Cash Flow
In the last 12 months, operating cash flow was -170.86M and capital expenditures -221K, giving a free cash flow of -171.08M.
| Operating Cash Flow | -170.86M |
| Capital Expenditures | -221K |
| Free Cash Flow | -171.08M |
| FCF Per Share | -2.41 |
Margins
Gross margin is 100%, with operating and profit margins of -283.57% and -245.96%.
| Gross Margin | 100% |
| Operating Margin | -283.57% |
| Pretax Margin | -245.74% |
| Profit Margin | -245.96% |
| EBITDA Margin | -276.11% |
| EBIT Margin | -283.57% |
| FCF Margin | -253.74% |
Dividends & Yields
ZNTL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ZNTL is $8, which is 447.9% higher than the current price. The consensus rating is "Hold".
| Price Target | $8 |
| Price Target Difference | 447.9% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -3.12 |
| Piotroski F-Score | 4 |